Minimal dose of aerosolized interferon-α in human subjects: Biological consequences and side-effects

European Respiratory Journal

Volumn 9, Issue 1, 1996, Pages 42-46

  Giosue S ^a,d   Casarini, M ^a   Ameglio, F ^b   Alemanno, L ^b   Saltini, C ^c   Bisetti, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d NONE   (Italy)

Author keywords

Aerosol; Bronchoalveolar lavage fluid; Chronic bronchitis; Interferon ; Oligoadenylate synthetase; Tetrazolium reduction

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; ALPHAN1 INTERFERON; LYMPHOBLAST INTERFERON;

ADULT; ARTICLE; BLOOD ANALYSIS; CHRONIC BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; LUNG LAVAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

2',5'-OLIGOADENYLATE SYNTHETASE; ADMINISTRATION, INHALATION; ADULT; BETA 2-MICROGLOBULIN; BIOPTERIN; BRONCHITIS; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; HUMANS; INTERFERON-ALPHA; LUNG; MALE; MIDDLE AGED; NEOPTERIN;

EID: 0030050021     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09010042     Document Type: Article

References (23)

1. Sattini C, Kirby M, Bisetti A, Crystal RG. The lung immune system. J Immunol Res 1991; 3: 43-48.
2. Saltini C, Kirby M, Trapnell B, Tamura N, Crystal RG. Biased accumulation of T-lymphocytes with "memory"-type CD45 leukocytes common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990; 171: 1123-1140.
3. Baren S, Stanton G, Fleischmann WR. Jr, Dianzani F, eds. In: The interferon system: a current review to 1987. Austin; University of Texas Medical Press, 1987; pp. 21-30.
4. Greenberg SB. Human interferon in viral disease. Infect Dis Clin North Am 1987; 1: 383-423.
5. Ho M. Interferon for the treatment of infections. Ann Rev Med 1987; 38: 51-59.
6. Bocci V. Evaluation of routes of administration of interferon in cancer: a review and proposal. Cancer Drug Deliv 1984; 1: 337-340.
7. Bocci V. Pharmacokinetics of interferons and routes of administration. Interferon. Principles and Medical Application. In: Baron S, Coppenhaver DH, Dianzani F, et al, eds. UTMB Press, 1992; pp. 417-425.
8. 125I-labelled human interferon-alpha is accompanied by partial loss of biological activity. Antiviral Res 1984; 4: 211-222.
9. Van Zandwijk N, Jassen E, Dubbelmann R, Braat MCP, Rumke P. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer 1990; 26: 738-740.
10. Kinnula V, Cantell K, Mattson K. Effect of inhaled natural interferon-alpha on diffuse bronchoalveolar carcinoma. Eur J Cancer 1990; 26: 740-741.
11. Debs RJ, Fuchs HJ, Philip R, et al. Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats. J Immunol 1988; 140: 3482-3488.
12. Maasilta P, Halme M, Mattson K, Cantell K. Pharmacokinetics of inhaled recombinant and natural alpha-interferon. Lancet 1991; 337: 371.
13. Kinnula V, Mattson K, Cantell K. Pharmacokinetics and toxicity of inhaled human interferon-α in patients with lung cancer. J Interferon Res 1989; 9: 419-423.
14. Chebath J, Revel M. The 2-5 A System: 2-5 A Synthetases, Isospecies and Functions. In: Interferon. Principles and Medical Application. Baron S, Coppenhaver DH, Dianzani F, et al, eds. UTMB Press, 1992; pp. 225-236.
15. Medical Reserch Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; 1: 775-779.
16. Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma and airflow obstruction: 25 years from the CIBA symposium. Thorax 1984; 39: 81-85.
17. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the SEP Task Group on BAL. Eur Respir J 1989; 2: 561-585.
18. Fuchs D, Hansen A, Reibnegger G. Neopterin as marker for activated cell-mediated immunity; application to HIV infection. Immunol Today 1988; 9: 150-155.
19. Dolei A, Ameglio F, Capobianchi MR. Human Interferon-γ enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than Interferon-α and Interferon-β. Infect Immun 1983; 40: 172-176.
20. Merritt JA, Borden EC, Ball LA. Measurement of 2′-5′ oligoadenylate synthetase in patients receiving interferon-α. J Interferon Res 1985; 5: 191-198.
21. Adams DO. Methods for studying mononuclear phagocytes. New York, Academic Press, 1981.
22. Boutin C, Viallat JR, Van Zandwiyk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67: 2033-2037.
23. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60(2): 532-538.